Using disease biology evidence for portfolio decisions that determine efficacy success
Generate disease biology understanding from human molecular and clinical data to inform target, indication, combination, and patient population decisions across drug development.
Proven Success
Trusted and validated by leading pharma companies
"We have prioritized AI partners with unique capabilities that can augment our development efforts ([..], CytoReason) and have achieved clinical or strong preclinical validation of their platforms"
Why It Matters
Every critical portfolio decision begins with a biological question
Access to information has never been easier. However, generating trusted disease biology understanding has never been harder.
{{ row.label }}
From Evidence to Impact
Turning disease biology evidence into better decisions
{{ s.n }}
{{ s.title }}
{{ s.body }}
Why CytoReason
Built to generate disease biology understanding
The most important portfolio decisions require more than data or predictions.
They require trusted disease biology understanding.
Portfolio Impact
Better biological decisions. Greater portfolio impact
{{ c.iconEl }}
{{ c.body }}